华润双鹤 (600062)
China Resources Double-crane Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameChina Resources Double-Crane Pharmaceutical Co., Ltd.
Listing Date1997-05-22
Issue Price6.69RMB
Registered Capital103875.750910k RMB
Legal RepresentativeZhao Qian
Registered AddressNo. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing
IndustryChemical Pharmaceuticals
Main BusinessProcessing and manufacturing of active pharmaceutical ingredients, injections, tablets, capsules, granules, pharmaceutical machinery and equipment; sales of self-produced products, mechanical and electrical equipment; technology development, technology transfer, technical services, etc.
Company ProfileChina Resources Double-Crane Pharmaceutical Co., Ltd. was founded in 1939. Originally a military pharmaceutical factory born in the Taihang Mountain revolutionary base area, it was named Lihua Pharmaceutical Factory. In 1949, it moved to Beijing with the army and was renamed Beijing Pharmaceutical Factory, developing into a large state-owned comprehensive chemical pharmaceutical preparation enterprise, laying the foundation for Beijing's modern chemical pharmaceutical industry. In 1997, it was listed on the Shanghai Stock Exchange and renamed Double-Crane Pharmaceutical Co., Ltd., expanding through external growth to become a cross-regional group based in Beijing and radiating nationwide. In 2010, following its original shareholder Beijing Pharmaceutical Group, it became part of the Fortune Global 500 enterprise China Resources Group. In 2012, it was renamed China Resources Double-Crane Pharmaceutical Co., Ltd. It is now a primary profit center of China Resources Group and the chemical drug business platform of China Resources Pharmaceutical Group.
Stock Details
1. Key Indicators
- Total Shares(W): 103875.75
- Circulating A-Shares(W): 103263.08
- Earnings Per Share(RMB): 1.3077
- Net Assets Per Share(RMB): 10.8962
- Operating Revenue(W RMB): 828322.24
- Total Profit(W RMB): 162085.41
- **Net Profit Attributable to Parent(W RMB) **: 134953.55
- Net Profit Growth Rate(%): -3.40
- Weighted Return on Equity(%): 12.3400
- Operating Cash Flow Per Share(RMB): 1.1040
- Undistributed Profit Per Share(RMB): 9.7282
- Capital Reserve Per Share(RMB): 0.1958
2. Main Business
The main business covers:
- Processing and manufacturing of formulated drugs
- Chemical and biological pharmaceutical raw materials
- Pharmaceutical packaging materials
3. Company Basic Information
- Company Name: China Resources Double-Crane Pharmaceutical Co., Ltd.
- Listing Date: 1997-05-22
- Industry: Pharmaceutical Manufacturing
- Address: No. 1 Lize East Second Road, Wangjing, Chaoyang District, Beijing
- Website: https://www.dcpc.com/
- Company Profile: The company was established on March 2, 1997, jointly initiated by Beijing Pharmaceutical Factory and others, with part of its assets converted into 89.5 million state shares and 10.5 million privately placed initiator legal person shares. After the issuance in May of the same year, the total share capital at the time of listing reached 147 million shares. Its 4.7 million internal employee shares will be listed for trading six months after the 42.3 million public shares were listed on May 22, 1997.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Beijing Pharmaceutical Group Co., Ltd. | General Legal Person | 62579.56 | 60.60 |
| 2 | Hong Kong Securities Clearing Company Limited | Northbound Capital | 929.33 | 0.90 |
| 3 | CSI 500 Exchange Traded Open-End Index Securities Investment Fund | Fund | 607.38 | 0.59 |
| 4 | China Foreign Economic and Trade Trust Co., Ltd. - Foreign Trade Trust - Renqiao Zeyuan Stock Private Securities Investment Fund | Private Securities Investment Fund | 247.37 | 0.24 |
| 5 | China Life Insurance Company Limited - Traditional - General Insurance Products - 005L-CT001 Shanghai | General Legal Person | 195.54 | 0.19 |
| 6 | HSBC Jintrust Value Pioneer Stock Securities Investment Fund Class A | Fund | 24.19 | 0.02 |
| 7 | Dongxing Dividend Preferred Hybrid Securities Investment Fund Class A | Fund | 4.20 | 0.00 |
| 8 | Xinyuan Medical Care Select Hybrid Initiation Securities Investment Fund Class A | Fund | 2.79 | 0.00 |
5. Concept Sectors
- Biological Vaccines
- Generic Drugs
- NMN Concept
- Innovative Drugs
- Weight Loss Drugs
- Synthetic Biology
- DeepSeek
- AI Healthcare
Remarks
- Data update date: 2025-09-30
- Data source: Public market information